|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,233.50 JPY | +1.06% |
|
+1.68% | +6.71% |
| 07-13 | Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug | MT |
| 07-10 | Health Care Down on Rotation Back to Tech - Health Care Roundup | DJ |
| Market Cap | 3,959B 24.19B 21.27B 19.8B 18.18B 34.14B 2,320B 34.59B 235B 91.9B 1,145B 90.81B 88.85B | P/E 2027 * |
11.5x | P/E 2028 * | 11.9x |
|---|---|---|---|---|---|
| Enterprise Value | 3,829B 23.4B 20.57B 19.15B 17.58B 33.02B 2,244B 33.45B 228B 88.88B 1,108B 87.82B 85.93B | EV / Sales 2027 * |
1.69x | EV / Sales 2028 * | 1.68x |
| Free-Float |
97.66% | Yield 2027 * |
3.63% | Yield 2028 * | 3.75% |
Last Transcript: Astellas Pharma Inc.
| 1 day | +1.06% | ||
| 1 week | +1.68% | ||
| Current month | +2.69% | ||
| 1 month | +2.88% | ||
| 3 months | -3.14% | ||
| 6 months | +4.76% | ||
| Current year | +6.71% |
| 1 week | 2,131.5 |  | 2,242.5 |
| 1 month | 2,105 | | 2,242.5 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,475 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 09/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 31/10/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 31/03/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 09/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 31/05/2019 |
| Director/Board Member | 58 | 31/05/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.06% | +1.68% | +49.90% | +7.38% | 24.19B | |
| +0.13% | +4.41% | +47.35% | +163.20% | 1,068B | |
| +0.97% | +6.88% | +58.02% | +53.12% | 641B | |
| -0.94% | +1.39% | +35.02% | +72.60% | 454B | |
| +0.32% | +8.06% | +38.41% | +33.89% | 351B | |
| +0.26% | +2.53% | +37.90% | +42.63% | 299B | |
| -1.01% | +2.08% | +18.18% | +15.32% | 266B | |
| +0.57% | +1.36% | -27.20% | -37.84% | 220B | |
| +0.06% | +3.32% | +22.73% | +59.40% | 203B | |
| +0.94% | -2.02% | +12.32% | +70.59% | 162B | |
| Average | +0.39% | +2.75% | +29.26% | +48.03% | 368.75B | |
| Weighted average by Cap. | +0.44% | +2.85% | +36.65% | +77.38% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,260B 13.81B 12.14B 11.3B 10.38B 19.48B 1,324B 19.74B 134B 52.45B 654B 51.82B 50.71B | 2,079B 12.7B 11.17B 10.39B 9.55B 17.93B 1,218B 18.16B 124B 48.26B 602B 47.68B 46.66B |
| Net income | 343B 2.09B 1.84B 1.71B 1.57B 2.95B 201B 2.99B 20.36B 7.95B 99.1B 7.86B 7.69B | 331B 2.02B 1.78B 1.65B 1.52B 2.85B 194B 2.89B 19.66B 7.68B 95.7B 7.59B 7.42B |
| Net Debt | -130B -795M -699M -650M -597M -1.12B -76.21B -1.14B -7.73B -3.02B -37.63B -2.98B -2.92B | -472B -2.89B -2.54B -2.36B -2.17B -4.07B -277B -4.13B -28.07B -10.96B -137B -10.83B -10.6B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/07/26 | JP¥2,233.50 | +1.06% | 7,062,100 |
| 27/07/26 | JP¥2,210.00 | +2.01% | 5,781,500 |
| 24/07/26 | JP¥2,166.50 | +0.25% | 4,657,000 |
| 23/07/26 | JP¥2,161.00 | -0.67% | 4,744,700 |
| 22/07/26 | JP¥2,175.50 | -0.96% | 7,982,000 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Select your edition
All financial news and data tailored to specific country editions
